Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR19034 Eye Drops for Slowing the Progression of Myopia in Children
NCT07844356Phase 3Completed
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atropine in myopia (3 arms), sponsored by Chengdu Suncadia Pharmaceuticals. Primary endpoint: Change from baseline in spherical equivalent refraction at 144 weeks. Started Oct 2021; status: completed.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on NCT07844356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07844356.